4-Octyl itaconate inhibits inflammation via the NLRP3 pathway in neuromyelitis optica spectrum disorders.

Ting LiJia-Wen LiYing-Hui QinRiu LiuXiao-Na XuXiao LiLi-Min LiBin FengLi YangChun-Sheng Yang

Published in: Annals of clinical and translational neurology (2024)

4-OI could effectively inhibit NLRP3 signaling, leading to the inhibition of proinflammatory cytokine production in patients with NMOSD-derived PBMCs and in a human macrophage model. Thus, 4-OI and itaconate could have important therapeutic value for the treatment of NMOSD in the future.

Keyphrases

endothelial cells
oxidative stress
current status
induced pluripotent stem cells
replacement therapy